ARx, LLC’s Post

Contract Pharma’s April issue is out now! Read the cover story about navigating #CDMO trends and more... #contractpharma #pharma #pharmanews

#Payer teams may grapple with the rise of specialty drugs. Discover how evidence-based technology and internal alignment can enhance efficiencies. Learn more in our new white paper. Download today! https://ow.ly/5MHh50T1cCT #Pharma #HealthcareInnovation #PayerEfficiency

#Payer teams may grapple with the rise of specialty drugs. Discover how evidence-based technology and internal alignment can enhance efficiencies. Learn more in our new white paper. Download today! https://ow.ly/VjyZ50T1eqm #Pharma #HealthcareInnovation #PayerEfficiency

A great snapshot into last week's #MedComms Forum hosted by NetworkPharma Ltd and sponsored by aps Events & Media. It was wonderful to see so many faces (old and new). Here are some of my key personal highlights: Session 1 - Event Landscapes, Insights, and Demands 💻 Face-to-face engagement is important; however, virtual and hybrid meetings are often more inclusive for those unable to attend in-person. 🤝 Medical societies need to engage with new audiences and reformulate sponsorship policies to focus on partnerships. 🎯 The industry needs to focus on key impact indicators as well as key performance indicators to provide maximal benefit to society. Session 2 - Compliance, 2024 Code 📜 Navigating national codes can be challenging, with compliance barriers (and company risk tolerance) often hindering meaningful patient engagement. 🗞 The updated ABPI code of conduct is expected in the 4th quarter of 2024, with a 3-month transition period planned upon publication. Session 3 - Patient Inclusion 🎙 Meaningful patient engagement can be realised when patients are involved in the planning, delivery, evaluation, and leadership of scientific congresses. 🔗 Congress organisers should consider integrated patient tracks and accessibility when planning meetings to ensure maximal impact for everyone involved. 💼 Education, networking, and collaboration are key reasons why patients want to attend scientific congresses. #MedicalCommunications #MedicalAffairs #MedAffairs #Pharma #PatientEngagement #PatientInvolvement #PatientsInvolved #PatientAdvocacy #PatientsIncluded #IntegratedPatientEngagement

At Zyfis Lifesciences, we understand the critical importance of staying informed on industry standards and best practices. The ICH M12 Q&A document on Drug Interaction Studies offers crucial insights and clarifications for conducting effective drug interaction research. Explore this comprehensive guide to enhance your understanding and implementation of drug interaction studies. #ClinicalResearch #DrugDevelopment #Pharma #ICHGuidelines #DrugInteractionStudies #ZyfisLifesciences #ResearchExcellence

💊 Keeping up with regulatory demands can be tough—especially when it comes to removing TiO2. Our TODAY'S webinar will help you navigate these challenges with real-world solutions and case studies. Register now to learn more! https://buff.ly/3YlAZnw #Pharma #TiO2

How can you ensure that your publications are achieving their intended impact and reaching and influencing #HCPs? 👉 Uncover the real impact of your publications within minutes using our Publication Impact dashboard. Access a sample dashboard here: https://ow.ly/fWOb50RtzGK #Pharma #PharmaIndustry #MedicalAffairs #MedAffairs #PublicationStrategy

Australia has a vibrant #clinicaltrials industry. Are you one of more than 8,000 of us? #ClinicalResearch #CRA #CRC #ClinicalTrials #TranslationalResearch #Research #ClinicalResearchProfessionals #Pharma #PharmaceuticalIndustry #RnD #MedTech #MedicalDevice #DeviceIndustry #DrugDevelopment #FirstInHuman #EarlyPhase #MedicalResearch #ClinicalStudies

This blog explores drug trends 📊📈📉 from the Telus drug trends benchmarking reports from both 2018 and now, comparing shifts and the reasons we think they might have happened. Plus, what's in store for the future! Drug trends findings from the annual TELUS benchmark reports https://hubs.ly/Q02D5Sgb0 #drugtrends #prescriptiondrugs #specialtydrugs #genericdrugs #pharmacare

See what you may have missed this week in pharma in today's Editors' (re)View, where our editors comment on the notable happenings in the industry. This week, Andrea Corona discusses the approval of AbbVie's Parkinson's drug. Read the full article with the link below. #EditorsReview #pharma #pharmaindustry #AbbVie #parkinsons #pharmanews #pharmamanufacturing https://lnkd.in/gC-nVwpT